ArticleCommunications medicine2025
Computational and biological modeling of IGF1R inhibition for multifocal medulloblastoma.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The insulin receptor inhibitor BMS-754807 alleviates neuroinflammation and Alzheimer's disease pathologies across human cellular and mouse models.Journal of neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeptomeningeal metastasis in medulloblastoma poses challenges for effective treatments due to the blood-brain barrier (BBB), which may be addressed through intrathecal or intraventricular drug delivery. However, the lack of pharmacokinetic modeling for pathological cerebrospinal fluid (CSF) geometries has limited the ability to predict effective intrathecal and intraventricular drug exposure.
methodsA patient-specific computational fluid dynamics "in silico" trial was conducted to simulate CSF movement to examine the tumor microenvironment in terms of drug-target exposure over time following intraventricular delivery via Omaya Reservoir. Simultaneously, we conducted cellular adhesion experiments to test the therapeutic potential of IGF1R inhibition on metastasis under patient-specific flow conditions generated by computational analysis.
resultsA 3-dimensional computational fluid dynamics (CFD) model based on patient-specific conditions was obtained to predict an efficacious drug concentration, providing guidance for therapeutic drug exposure at targeted sites. Microfluidic experiments for IGF1R inhibition of cellular adhesion showed the potential for reduced attachment of medulloblastoma to leptomeningeal cells to prevent metastasis.
conclusionsThis study offers insights from patient-specific in silico trials for the precision delivery of small-molecule drugs for the treatment of central nervous system (CNS) malignancies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.